SOURCE: ChromoCure, Inc.

March 01, 2010 13:50 ET

ChromoCure Completes Realignment of Management as First Step in Transition to Cancer Therapy and Cure Research & Development

RENO, NV--(Marketwire - March 1, 2010) -  ChromoCure, Inc. (PINKSHEETS: KKUR) announced today the completion of the first major step in its transition to a focused Cancer Therapy and Cure Research & Development organization. The Company recently announced its accelerated Therapy and Cure initiatives through the launch of Project Boveri: Find the Cure; properly reflecting its pioneering role in cancer detection, therapy and cure; and its increased research programs and collaborations.

This major realignment of the Company's business strategy includes the departure of all prior management. The Company will soon announce its new management team with proven credentials to maintain ChromoCure's leadership and pioneering role in Cancer Therapy and Cure initiatives worldwide.

As recently announced the Company had realigned its business strategy due to corroboration by recent Medical Research publications that both validated ChromoCure's chromosomal/aneuploidy theory of cancer and immediately established the company's proprietary Chromosomal Scanner technology in the forefront of both cancer detection and research.

Research has conclusively, and irrefutably demonstrated aneuploidy as a more accurate predictor of cancer than cytological/histological analysis or genetic marker-based diagnostics that are the only other methods in existence today. ChromoCure's proprietary technology and understanding of cancer also suggest non-toxic and non-invasive approaches to cancer therapy and cure research. 

The company's technology and research combined with unique insights provided by the chromosomal theory of cancer paves the way for non-invasive and non-toxic solutions to cancer therapeutics and disease eradication. ChromoCure's ChromoSomal Scanner Technologies, encompassing proprietary designs, processes, and algorithms, provides significant advantage in delivering important and significant results in diagnosis therapy and cure.

Support by these recent third party medical findings, the Company is calling for a stepped up collaborative approach through its "Project Boveri: Find the Cure" initiative; and is inviting industry, institutions, medical research centers and government to partner in this initiative. The company has already established a special section of its web site dedicated to this project and research outreach. The Company's recently announced diagnostic partnership program with pathologists and diagnostic labs will be incorporated into Project Boveri in order to broaden awareness of the company's technology.

The company will provide timely updates on new management as well as progress reports on new management appointments; as well as partnerships, products, licensing, and laboratory activities based on this research-oriented alignment.

About ChromoCure
ChromoCure develops and provides proprietary cancer detection systems and related therapeutic technologies. The Company's proprietary CS200 Chromosomal Scanner has been proven accurate and efficient in the measurement of the unique genomic characteristic found in 100% of all cancers and never found in normal cells. The Company's detection technology has an effective accuracy of 100% for all cancers at all stages. The Company believes its technology will become the worldwide gold standard for cancer detection, progression measurement, and research for both therapy and cure.
The Company also applies its technology and knowledge to cancer cure and therapeutics research.

Safe-Harbor Statement
This release contains statements or projections regarding future performance that is forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those projected as a result of certain risks and uncertainties. The company's filings contain various RISK FACTORS (and are incorporated herein by reference) and should be read before any investment decision.

Contact Information